Shanghai, China, 28 July 2022 — MicroPort® Soaring CRM (Shanghai) Co., Ltd. (“MSC”) recently announced the first batch of the Rega™ MRI-conditional implantable pacemakers was used at several medical centers, including Fuwai Hospital Chinese Academy of Medical Sciences, Zhongshan Hospital; affiliated to Fudan University, Shanxi Institute of Cardiovascular Diseases, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Dalian Medical University, and First Affiliated Hospital of Zhengzhou University. These implants mark the first official clinical use of a MRI-conditional pacemaker in China.
Magnetic resonance imaging (MRI) is considered one of the most important diagnostic techniques in clinical practice and has been widely used around the world. Yet in the past MRI was prohibited for patients with pacemakers. Following the use of MRI-conditional technology in pacemakers, more patients can safely undergo MRI examinations even after pacemaker implantation.
As the first domestic pacemaker compatible with MRI examination, the Rega™ pacemaker series has adopted the state-of-the-art AutoMRI™ technology, which activates the MRI examination mode automatically upon detecting the magnetic field of an MRI device. After implantation, the AutoMRI™ technology deactivates the MRI examination mode as soon as the patient leaves the magnetic field environment. This feature allows the pacemaker to maintain optimal parameter settings before and after entering the magnetic field environment, reducing the need for an on-site physician intervention and minimizing discomfort and the risk of arrhythmias to the patient.
After the first implantation, Prof. Wei Hua, Chair of the Chinese Society of Pacing and Electrophysiology, Chinese Medical Association and Director of the Cardiac Arrhythmia Diagnosis and Treatment Center of Fuwai Hospital, Chinese Academy of Medical Sciences commented, “MRI conditional pacing systems are becoming the norm in pacing therapy, increasingly welcomed by doctors and patients alike.” Prof. Wei Hua adds, “The Rega™ pacemaker is the first domestic pacemaker approved by the National Medical Products Administration that can safely undergo MRI under certain conditions. Not only does it inherit the comprehensive features of its predecessor, including compact design, long life, and physiological features, but its AutoMRI™ technology offers more distinct advantages in clinical applications, which reduce physician intervention and medical resource usage while safeguarding patient safety and enabling a flexible workflow.”
Mr. Xiaoming Zhu, General Manager of MSC, commented, “We thank the experts and professors who pioneer the application of the Rega™ MRI-conditional safe pacemakers. This is a recognition of the audacious innovation of domestic pacemakers. We look forward to seeing more patients benefit from this advanced medical technology and further improve their quality of life while undergoing life-saving treatment. I would thank all MSC staff for their efforts that enabled us to take another solid step forward in gaining world leadership in quality.”
Dr. Qiyi Luo, Chairman of MSC, said, “MSC has always been committed to providing a comprehensive solution for patients with cardiac arrhythmias. We will continue to serve the patients and launch a full range of innovative technologies and quality products for heart rhythm management by keeping clinical needs in mind. We will also actively cooperate with doctors to advance the promotion and application of pacing therapy in China.”
MicroPort Soaring CRM (Shanghai) Co., Ltd. (MSC) is a subsidiary of MicroPort Scientific Corporation (00853.HK). MSC has an aim to provide quality and affordable CRM products and services to patients in China. In the future, MSC will continue to factor in the clinical needs of patients and doctors in China and offer more targeted and refined cardiology treatment and management solutions. By promoting academic exchanges and sharing among clinicians, MSC is committed to promoting innovative solutions for more patients with heart disease.